Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Physicians Should Also Be Forbidden to Receive Gifts: Maker FTC
July 2, 2001
- REGULATORY NEWS IN BRIEF
July 2, 2001
- Bayer AG to Increase Share in Asia-Pacific from 16% to 25%
July 2, 2001
- Japan Is Lagging Behind the US in Life Science: S&T White Paper
July 2, 2001
- M&A, Alliance Effective for Strengthening R&D Ability: EAD Director
July 2, 2001
- CORPORATE ROUNDUP
July 2, 2001
- Aventis Aiming to Achieve Highest Growth Rate in Japan: President Loescher
July 2, 2001
- Council for Regulatory Reform to Focus on Medical Fees, NHI Prices
July 2, 2001
- Blopress, Nu-lotan Up Remarkably, But Mevalotin, Lipovas Down: Top 100 Products
July 2, 2001
- 48 New Active Ingredients Approved in FY2000
July 2, 2001
- Otsuka to Acquire Meretek of the US
July 2, 2001
- Takeda's Ixense for ED Launched in France, Germany
July 2, 2001
- MEDICAL DEVICE NEWS IN BRIEF
July 2, 2001
- Kyowa Hakko to Sell Mohan to Merck Hoei
July 2, 2001
- WORLD NEWS IN BRIEF
July 2, 2001
- Dainippon Launches Gasmotin in China
July 2, 2001
- OTC NEWS IN BRIEF
July 2, 2001
- EAD Director Urges Generic Houses to Expand Their Sales Route
July 2, 2001
- Takeda to Invest \110 Billion in R&D for FY2001
July 2, 2001
- 14 New Ingredients Officially Clear Regulatory Approval
July 2, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…